Bavarian Nordic begins Phase 1 clinical trial of MVA-BN® WEV vaccine
Category: #health  By Paroma Bhattacharya  Date: 2019-10-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Bavarian Nordic begins Phase 1 clinical trial of MVA-BN® WEV vaccine

The trial will reportedly examine the safety, tolerability and immunogenicity of MVA-BN WEV

The U.S. is currently facing the worst outbreak of the Eastern equine encephalitis virus (EEEV). Over 30 cases were reported in 2019, which included 9 fatalities, majorly in the north-eastern regions of the country, where mosquitoes have been found to carry the virus.

Denmark-based biotechnology company Bavarian Nordic recently announced the commencement of the first-in-human trial of its prophylactic vaccine candidate, MVA-BN® WEV, for the prevention of equine encephalitis virus.

Reportedly funded by the U.S. Department of Defense Joint Project Manager for Chemical, Biological, Radiation and Nuclear Medicine (JPM CBRN Medical), the project is a multi-year agreement valued at $36 million that aims to formulate a vaccine against three different forms of the equine encephalitis virus – Eastern (EEEV), Venezuelan and (VEEV)Western (WEEV). Currently, there are no preventive vaccines available for the virus.

The Phase 1 trial will evidently analyze the safety, efficacy and tolerability of MVA-BN WEV in 45 healthy adults divided into three treatment groups which will be administered with different doses of the vaccine. It is estimated that promising results from the study will be achieved and available by 2020.

Sources familiar with the matter reported that a successful Phase 1 trial, based on demonstrating favorable safety and efficacy, could lead to additional funding beyond the initial USD 36 million contract award, to promote further clinical, preclinical development and manufacturing to obtain licensure in the U.S.

Bavarian Nordic President and CEO Paul Chaplin was reported saying that following the recent FDA approval of its smallpox vaccine, which was formulated in collaboration with numerous U.S. Government agencies and has become a vital part of the national stockpile, the company looks forward to advancing the new & innovative program and help realize the U.S. government’s goal to develop a wide range of medical countermeasures to protect U.S. citizens.

The occurrence of Triple E virus has significantly increased in US, highlighting the need to develop a vaccine to tackle the disease. To address the unmet medical needs, the company will utilize the unique properties of its MVA-BN platform technology and expects to continue the effort with DOD on the critical project, Chaplin noted.  

Source Credits –http://www.bavarian-nordic.com/investor/news/news.aspx?news=5768



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
By Paroma Bhattacharya

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from P...

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...